Cartron J P, Ferrari B, Huet M, Pavia A A
Laboratoire de Biochimie Génétique, Inserm, U-76, Centre National de Transfusion Sanguine, Paris, France.
Exp Clin Immunogenet. 1984;1(2):112-6.
The specificity of a human anti-Mg antibody has been evaluated by agglutination-inhibition assays using several peptides and glycopeptides structurally related to the N-terminal end of glycophorin A, which were obtained by chemical synthesis. We have shown that the anti-Mg antibody is strongly inhibited by pentapeptides containing a leucine residue at their N-terminal end. Glycosylations of these peptides at positions 2, 3 and 4 by N-acetylgalactosamine and/or galactose-beta 1-3-N-acetylgalactosamine units abolish the biological activity, as well as the masking of the leucine residue by addition of N-acetylglycine. The results demonstrate also that the presence of an asparagine residue at position 4 of the pentapeptides (or glycopeptides) is not a requirement for Mg specificity and suggest that the antibody recognizes primarily a nonglycosylated peptide structure with an N-terminal leucine residue.
通过凝集抑制试验,利用几种与血型糖蛋白A N端结构相关的肽和糖肽,对一种人抗Mg抗体的特异性进行了评估,这些肽和糖肽是通过化学合成获得的。我们已经表明,抗Mg抗体在其N端含有亮氨酸残基的五肽的强烈抑制作用。这些肽在第2、3和4位被N-乙酰半乳糖胺和/或β1-3-半乳糖-N-乙酰半乳糖胺单元糖基化会消除其生物活性,通过添加N-乙酰甘氨酸掩盖亮氨酸残基也会消除其生物活性。结果还表明,五肽(或糖肽)第4位存在天冬酰胺残基并非Mg特异性所必需,并表明该抗体主要识别具有N端亮氨酸残基的非糖基化肽结构。